0001628280-22-018182.txt : 20220628 0001628280-22-018182.hdr.sgml : 20220628 20220628172931 ACCESSION NUMBER: 0001628280-22-018182 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220627 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220628 DATE AS OF CHANGE: 20220628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd. CENTRAL INDEX KEY: 0001689813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38080 FILM NUMBER: 221051180 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 8-K 1 bhvn-20220627.htm 8-K bhvn-20220627

Washington, DC 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 27, 2022
Biohaven Pharmaceutical Holding Company Ltd.
(Exact name of registrant as specified in its charter)
British Virgin Islands001-38080Not applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
c/o Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven, Connecticut 06510
(Address of principal executive offices, including zip code)
(203) 404-0410
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Shares, no par valueBHVNNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 8.01Other Events
As previously disclosed, on May 9, 2022, Biohaven Pharmaceutical Holding Company Ltd., a British Virgin Islands business company limited by shares (“Biohaven” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Pfizer Inc., a Delaware corporation (“Pfizer”), and Bulldog (BVI) Ltd., a British Virgin Islands business company limited by shares and a wholly owned subsidiary of Pfizer (“Merger Sub”), pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Biohaven (the “Merger”).

The completion of the Merger is conditioned upon, among other things, expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) relating to the consummation of the Merger. The applicable waiting period under the HSR Act expired at 11:59 p.m., Eastern time, on June 27, 2022. In addition to antitrust approval in the United States, the Merger was cleared by the German Federal Cartel Office on June 13, 2022 and was cleared by the Austrian Federal Competition Authority on June 23, 2022. On June 24, 2022, in response to a briefing paper filed by Pfizer on May 20, 2022, the UK Competition & Markets Authority confirmed that no further information is required on the Merger.

The completion of the Merger remains subject to other closing conditions, including (i) the receipt of the required approval from Company shareholders, (ii) the completion of a pre-closing reorganization by the Company, which will result in (x) Biohaven Research Ltd., a British Virgin Islands business company limited by shares and a wholly owned subsidiary of the Company (“SpinCo”) owning, assuming or retaining certain assets and liabilities of the Company and its subsidiaries related to the Company’s pipeline assets and businesses, and (y) the Company owning, assuming or retaining all other assets and liabilities, including those associated with the Company’s platform for the research, development, manufacture and commercialization of calcitonin gene-related peptide receptor antagonists, including rimegepant, zavegepant and the Heptares Therapeutics Limited pre-clinical CGRP portfolio and (iii) following such pre-closing reorganization, the distribution by the Company to its shareholders as of the record date all of the issued and outstanding common shares of SpinCo, no par value, on a pro rata basis.

Additional Information and Where to Find It
In connection with the proposed transaction, Biohaven will be filing documents with the United States Securities and Exchange Commission (the “SEC”), including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy statement will be mailed to Biohaven’s shareholders in connection with the proposed transaction. This communication is not a substitute for the proxy statement or any other document that may be filed by Biohaven with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any vote in respect of resolutions to be proposed at Biohaven’s shareholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the information contained in Biohaven’s proxy statement. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC’s web site at www.sec.gov or on Biohaven’s website at https://www.biohavenpharma.com/investors.

No Offer or Solicitation

This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.


Participants in Solicitation

Biohaven and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about Biohaven’s directors and executive officers is set forth in its proxy statement for its 2022 annual meeting of shareholders, which was filed with the SEC on March 11, 2022. Other information regarding participants in the proxy solicitations in connection with the proposed transaction, and a description of any interests that they have in the proposed transaction, by security holdings or otherwise, in the proposed transaction will be included in the proxy statement described above. These documents are available free of charge at the SEC’s web site at www.sec.gov and by going to Biohaven’s website at https://www.biohavenpharma.com/investors.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit NumberExhibit Description
104The cover page of this Current Report on Form 8-K formatted as Inline XBRL.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 28, 2022
Biohaven Pharmaceutical Holding Company Ltd.
By:/s/ Matthew Buten
Matthew Buten
Chief Financial Officer

EX-101.SCH 2 bhvn-20220627.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 bhvn-20220627_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 4 bhvn-20220627_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Jun. 27, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 27, 2022
Entity Registrant Name Biohaven Pharmaceutical Holding Company Ltd.
Entity Central Index Key 0001689813
Amendment Flag false
Entity Incorporation, State or Country Code D8
Entity File Number 001-38080
Entity Address, Address Line One c/o Biohaven Pharmaceuticals, Inc.
Entity Address, Address Line Two 215 Church Street
Entity Address, City or Town New Haven
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06510
City Area Code 203
Local Phone Number 404-0410
Written Communications false
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol BHVN
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 6 bhvn-20220627_htm.xml IDEA: XBRL DOCUMENT 0001689813 2022-06-27 2022-06-27 0001689813 false 8-K 2022-06-27 Biohaven Pharmaceutical Holding Company Ltd. D8 001-38080 c/o Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510 203 404-0410 false true false false Common Shares, no par value BHVN NYSE false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.biohavenpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bhvn-20220627.htm bhvn-20220627.xsd bhvn-20220627_lab.xml bhvn-20220627_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bhvn-20220627.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "bhvn-20220627.htm" ] }, "labelLink": { "local": [ "bhvn-20220627_lab.xml" ] }, "presentationLink": { "local": [ "bhvn-20220627_pre.xml" ] }, "schema": { "local": [ "bhvn-20220627.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bhvn", "nsuri": "http://www.biohavenpharma.com/20220627", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220627.htm", "contextRef": "i3ded14fe01ff4a73b738d918df1a1ecb_D20220627-20220627", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.biohavenpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20220627.htm", "contextRef": "i3ded14fe01ff4a73b738d918df1a1ecb_D20220627-20220627", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biohavenpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001628280-22-018182-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-018182-xbrl.zip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ļ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end